Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status.

ABSTRACT:

Objective

The objective of this study was to characterize changes in body weight and glycated hemoglobin (in those with prediabetes at baseline) through 12 months by obesity pharmacotherapy discontinuation status.

Methods

This retrospective cohort study used electronic health record data from a large health system in Ohio and Florida to identify adults with overweight or obesity without type 2 diabetes who initiated injectable semaglutide or tirzepatide between 2021 and 2023. Treatment discontinuation was defined by a >90-day gap between exhaustion of previous supply and next dispense or end of study follow-up (December 2024) and was classified into early discontinuation (i.e., within 3 months of index date) and late discontinuation (i.e., within 3-12 months).

Results

SUBMITTER: Gasoyan H 

PROVIDER: S-EPMC12381620 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature